Protein kinase C regulates ezrin-radixin-moesin phosphorylation in canine osteosarcoma cells

被引:29
作者
Hong, S. -H. [1 ]
Osborne, T. [1 ]
Ren, L. [1 ]
Briggs, J. [1 ]
Mazcko, C. [2 ]
Burkett, S. S. [3 ]
Khanna, C. [1 ,2 ]
机构
[1] NCI, Tumor & Metastasis Biol Sect, Pediat Oncol Branch, Ctr Canc Res,NIH, Bethesda, MD 20892 USA
[2] NCI, Comparat Oncol Program, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[3] NCI, Mouse Canc Genet Program, NIH, Frederick, MD 21701 USA
关键词
dog; ezrin; metastasis; osteosarcoma; PKC; GENE-EXPRESSION; CARCINOMA-CELLS; LINKER EZRIN; METASTASIS; TUMORS; MODEL; MELANOMA; SURVIVAL; BIOLOGY; DOG;
D O I
10.1111/j.1476-5829.2010.00249.x
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
The development of metastasis is the most significant cause of death for both canine and human patients with osteosarcoma (OS). Ezrin has been associated with tumour progression and metastasis in human, canine and murine OS. Ezrin activation is dynamically regulated by protein kinase C (PKC) during metastatic progression in human and murine OS. To include the dog in the development of therapeutics that target ezrin biology, we characterized four new canine OS cell lines and confirmed the relationship between PKC and ezrin in these cells. Three of four cell lines formed tumours in mice that were histologically consistent with OS. All cell lines were markedly aneuploid and expressed ezrin and PKC. Finally, both ezrin phosphorylation and cell migration were inhibited using a PKC inhibitor. These data suggest that an association between PKC-mediated activation of ezrin and the metastatic phenotype in canine OS cells.
引用
收藏
页码:207 / 218
页数:12
相关论文
共 29 条
[1]   A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma [J].
Ajani, JA ;
Jiang, YX ;
Faust, J ;
Chang, BCB ;
Ho, L ;
Yao, JC ;
Rousey, S ;
Dakhil, S ;
Cherny, RC ;
Craig, C ;
Bleyer, A .
INVESTIGATIONAL NEW DRUGS, 2006, 24 (04) :353-357
[2]  
Bohling T, 1996, AM J PATHOL, V148, P367
[3]   ERM proteins and merlin: Integrators at the cell cortex [J].
Bretscher, A ;
Edwards, K ;
Fehon, RG .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2002, 3 (08) :586-599
[4]   Expression of the cytoskeleton linker protein ezrin in human cancers [J].
Bruce, Benjamin ;
Khanna, Gaurav ;
Ren, Ling ;
Landberg, Goran ;
Jirstrom, Karin ;
Powell, Charles ;
Borczuk, Alain ;
Keller, Evan T. ;
Wojno, Kirk J. ;
Meltzer, Paul ;
Baird, Kristin ;
McClatchey, Andrea ;
Bretscher, Anthony ;
Hewitt, Stephen M. ;
Khanna, Chand .
CLINICAL & EXPERIMENTAL METASTASIS, 2007, 24 (02) :69-78
[5]   On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy [J].
Bruland, OS ;
Pihl, A .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (11) :1725-1731
[6]   The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells [J].
Elliott, BE ;
Meens, JA ;
SenGupta, SK ;
Louvard, D ;
Arpin, M .
BREAST CANCER RESEARCH, 2005, 7 (03) :R365-R373
[7]   Ezrin, a key component in tumor metastasis [J].
Hunter, KW .
TRENDS IN MOLECULAR MEDICINE, 2004, 10 (05) :201-204
[8]   Ezrin in primary cutaneous melanoma [J].
Ilmonen, S ;
Vaheri, A ;
Asko-Seljavaara, S ;
Carpen, O .
MODERN PATHOLOGY, 2005, 18 (04) :503-510
[9]   Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors [J].
Jimeno, Antonio ;
Rudek, Michelle A. ;
Purcell, Thomas ;
Laheru, Daniel A. ;
Messersmith, Wells A. ;
Dancey, Janet ;
Carducci, Michael A. ;
Baker, Sharyn D. ;
Hidalgo, Manuel ;
Donehower, Ross C. .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (03) :423-433
[10]   Matrix metalloproteinase-9 is required for tubular network formation and migration of resistant breast cancer cells MCF-7 through PKC and ERK1/2 signalling pathways [J].
Karroum, Asmae ;
Mirshahi, Pezhman ;
Benabbou, Nadia ;
Faussat, Anne-Marie ;
Soria, Jeannette ;
Therwath, Amu ;
Mirshahi, Massoud ;
Hatmi, Mohamed .
CANCER LETTERS, 2010, 295 (02) :242-251